Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Gen-Probe; Molecular Devices, Genetix; Ontario Genomics Institute; Waters

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Gen-Probe said this week that its Gen-Probe Life Sciences division has completed the consolidation of its molecular genetic services business into its newly expanded facilities in Manchester, UK. The life sciences division already provides nucleic acid extraction and array-based services and plans to further develop a suite of genomic services aimed at the R&D stage of drug development, such as biomarker qualification and validation.

Danaher company Molecular Devices this week said that the drug discovery division of Genetix will join its operations. Genetix, which also is owned by Danaher, sells the ClonePix and QPix cell research instruments, which are complementary to offerings from Molecular Devices.

The Ontario Genomics Institute has awarded its Societal Impact of Genomics Prize to Abdallah Daar and Sarah Ali-Khan of the McLaughlin-Rotman Centre for Global Health, University Health Network and University of Toronto. They were awarded the $10,000 prize for their research into genomics and race.

Waters said this week that the metabolomics program at Georgetown University Medical Center has joined the firm's Centers of Innovation Program. Other members of the program include labs at Kings College London, Imperial College London, Duke University, University California Davis, Northeastern University, and the University of Warwick.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.